J E Blaney

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 21:4317-27. 2003
  2. ncbi request reprint Genetically modified, live attenuated dengue virus type 3 vaccine candidates
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Am J Trop Med Hyg 71:811-21. 2004
  3. pmc The effect of volume of interest definition on quantification of lymph node immune response to a monkeypox virus infection assessed by (18)F-FDG-PET
    Svetlana Chefer
    Division of Clinical Research, Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD, 21702, USA
    EJNMMI Res 4:49. 2014
  4. pmc Antiviral activity of the EB peptide against zoonotic poxviruses
    Sharon E Altmann
    Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 9:6. 2012
  5. pmc Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, NIH, NIAID, LID Twinbrook III, Room 3W 13, 12735 Twinbrook Parkway, MSC 8133, Bethesda, MD 20892 8133, USA
    J Virol 79:5516-28. 2005
  6. pmc Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
    Joseph E Blaney
    Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:10605-16. 2011
  7. pmc Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
    Vaccine 26:817-28. 2008
  8. pmc Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 4:23. 2007
  9. ncbi request reprint Development of a live attenuated dengue virus vaccine using reverse genetics
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, LID, Bethesda, Maryland 20892 8133, USA
    Viral Immunol 19:10-32. 2006
  10. pmc Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice
    J E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:9731-40. 2001

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 21:4317-27. 2003
    ..The importance of these Vero cell adaptation mutations in flavivirus vaccine design and development is discussed...
  2. ncbi request reprint Genetically modified, live attenuated dengue virus type 3 vaccine candidates
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Am J Trop Med Hyg 71:811-21. 2004
    ..Thus, the rDEN3/4(ME) and rDEN3/4Delta30(ME) antigenic chimeric viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine...
  3. pmc The effect of volume of interest definition on quantification of lymph node immune response to a monkeypox virus infection assessed by (18)F-FDG-PET
    Svetlana Chefer
    Division of Clinical Research, Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD, 21702, USA
    EJNMMI Res 4:49. 2014
    ....
  4. pmc Antiviral activity of the EB peptide against zoonotic poxviruses
    Sharon E Altmann
    Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 9:6. 2012
    ..To expand on this work, we evaluated EB for in vitro activity against the zoonotic orthopoxviruses cowpox and monkeypox and for in vivo activity in mice against vaccinia and cowpox...
  5. pmc Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, NIH, NIAID, LID Twinbrook III, Room 3W 13, 12735 Twinbrook Parkway, MSC 8133, Bethesda, MD 20892 8133, USA
    J Virol 79:5516-28. 2005
    ..However, two doses of TV-2 or TV-3 induced protection against DEN2 challenge. Two tetravalent formulations, TV-2 and TV-3, possess properties of a successful DEN vaccine and can be considered for evaluation in clinical trials...
  6. pmc Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
    Joseph E Blaney
    Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:10605-16. 2011
    ....
  7. pmc Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
    Vaccine 26:817-28. 2008
    ..In addition, rDEN3Delta30/31 had reduced replication in Toxorynchites mosquitoes following intrathoracic inoculation. The results are discussed in the context of vaccine development and the physical structure of the DENV 3'-UTR...
  8. pmc Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 4:23. 2007
    ....
  9. ncbi request reprint Development of a live attenuated dengue virus vaccine using reverse genetics
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, LID, Bethesda, Maryland 20892 8133, USA
    Viral Immunol 19:10-32. 2006
    ..The level of attenuation of each dengue vaccine component can be increased, if needed, by introduction of additional attenuating mutations that have been well characterized...
  10. pmc Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice
    J E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:9731-40. 2001
    ..We are assembling a menu of attenuating mutations that should be useful in generating satisfactorily attenuated recombinant dengue vaccine viruses and in increasing our understanding of the pathogenesis of dengue virus...
  11. pmc Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 USA
    BMC Infect Dis 4:39. 2004
    ..To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate...
  12. ncbi request reprint Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice
    J E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda 20892, USA
    Arch Virol 148:999-1006. 2003
    ..The usefulness of such mutations in flavivirus vaccine design and development is discussed...
  13. ncbi request reprint Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Virology 300:125-39. 2002
    ....
  14. ncbi request reprint Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity
    Kathryn A Hanley
    Laboratory of Infectious Diseases LID, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 22:3440-8. 2004
    ..The application of these attenuating mutations to flavivirus vaccine development is discussed...
  15. pmc Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3203, USA
    Vaccine 26:4150-9. 2008
    ..These viruses may be considered for use as SLE vaccine candidates and for use as diagnostic reagents with reduced virulence...
  16. pmc Targeted mutagenesis as a rational approach to dengue virus vaccine development
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Room 3W10A, Bethesda, MD 20892 3203, USA
    Curr Top Microbiol Immunol 338:145-58. 2010
    ..Clinical studies of rDEN4Delta30-4995 are ongoing...
  17. ncbi request reprint Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 6515, Building 50, 50 South Drive, Bethesda, MD 20892 8007, USA
    Vaccine 21:4307-16. 2003
    ....
  18. ncbi request reprint Prospects for a dengue virus vaccine
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 5:518-28. 2007
    ..In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future...
  19. ncbi request reprint A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4
    Kathryn A Hanley
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 312:222-32. 2003
    ..The opposing effects of the NS4B P101L mutation in mosquito and vertebrate systems suggest that the NS4B protein is involved in maintaining the balance between efficient replication in the mosquito vector and the human host...
  20. pmc Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route
    Reed F Johnson
    National Institutes of Health, NIAID EVPS, Bethesda, MD 20892, USA
    J Virol 85:2112-25. 2011
    ..b. MPXV model should be considered for the further investigation of viral pathogenesis and countermeasures...
  21. pmc Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes
    Kathryn A Hanley
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:525-31. 2002
    ..This large set of charge-to-alanine mutations specifying a wide range of attenuation for mouse brain should prove useful in fine-tuning recombinant live attenuated DEN vaccines...
  22. ncbi request reprint rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 191:710-8. 2005
    ..The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu)...
  23. ncbi request reprint The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Hum Vaccin 2:167-73. 2006
    ..These promising preclinical studies have identified rDEN1Delta30 as a candidate DEN1 vaccine virus for further testing in a human Phase I clinical trial...
  24. ncbi request reprint rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Hum Vaccin 2:255-60. 2006
    ..The Delta30 mutation remained unchanged in each isolate, confirming the stability of the Delta30 mutation. Further evaluation of this vaccine in a tetravalent formulation is warranted...
  25. ncbi request reprint Arguments for live flavivirus vaccines
    Brian R Murphy
    Lancet 364:499-500. 2004